Objectives: Detection of rarer carbapenemases is challenging, as it requires molecular assays with comprehensive coverage or the use of phenotypic methods for the detection of carbapenemase activity. We describe a new class A carbapenemase, FRI-2, in an Enterobacter cloacae complex isolate following implementation of an inhouse multiplex PCR for the detection of 'rare' class A carbapenemases.
Introduction
In Enterobacteriaceae, carbapenem resistance mediated by carbapenemases is mostly attributed to the interspecies dissemination of KPC, OXA-48-like, NDM, VIM and IMP alleles. Although the dispersion of the 'big 5' carbapenemases has been reported worldwide, some carbapenemases, such as bla SME or bla SPM , are still species-or, largely, country-specific. 1, 2 Class A carbapenemases other than KPC include the closely related NMC-A and IMI, SME, GES, BIC-1, SFC-1 and BKC-1. 3 The detection of these carbapenemases poses a problem in terms of infection prevention and control as most commercial and in-house molecular assays have limited coverage and focus on the detection of the 'big 5' families. Moreover, due to the rarity of these other carbapenemases and their potential susceptibility to cephalosporins, phenotypic tests could be misinterpreted as falsepositives if further extended molecular characterization is not undertaken. 4 Dortet et al. 5 recently identified a novel class A carbapenemase, FRI-1, in an isolate of Enterobacter cloacae in a patient in France. FRI-1 shares 53% and 42% identity with SFC-1 and BKC-1, respectively, and is related to a subgroup including SME-1, IMI-1 and NMC-A, with identity ranging from 54% to 56%.
PHE's Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit has recently implemented an in-house multiplex PCR for the detection of the 'rare' class A carbapenemases FRI, IMI, GES and SME. During screening of clinical isolates sent to the AMRHAI Reference Unit for investigation of carbapenem resistance, we identified a variant of FRI-1 in an E. cloacae complex strain, subsequently named FRI-2.
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Materials and methods
An E. cloacae complex isolate 587 was submitted to PHE's AMRHAI Reference Unit in June 2016 for investigation of carbapenem resistance. This isolate was recovered from a patient who attended an outpatient clinic at the University Hospital of South Manchester (UK) and as part of routine assessment prior to a coronary artery bypass graft underwent rectal screening for carbapenemase-producing Enterobacteriaceae (CPE). Rectal screening for CPE using culture is routine for patients at higher risk of CPE carriage (including those admitted to hospitals in Greater Manchester in the previous year). 6 The patient had been admitted for cardiac problems in two hospitals in England including the referring hospital in the year before detection. The patient had no recent history of antibiotic administration or travel abroad. No previous CPE had been isolated from this patient, although there had been no previous rectal screening for CPE.
MICs were determined by agar dilution against AMRHAI's standard Gram-negative antibiotic panel, which includes imipenem (+EDTA for MBL detection), ertapenem and meropenem (+avibactam for class A carbapenemases detection), and interpreted using EUCAST criteria. 7 Carbapenemase genes, including various class A carbapenemases (bla KPC , bla FRI , bla IMI , bla GES , bla SME ) were sought using in-house multiplex ) and SME (SME-F: 5 0 -AAC GGC TTC ATT TTT GTT TAG-3 0 and SME-R: 5 0 -GCT TCC GCA ATA GTT TTA TCA-3 0 ) enzymes. Evidence of carbapenemase activity was sought using Rapidec
Etoile, France) and the carbapenem inactivation method (CIM). 9 Electroporation was performed using Escherichia coli Alpha-Select recipient cells (Bioline, London, UK). Transformants were selected on LB agar (Oxoid Ltd, Basingstoke, UK) containing 100 mg/L ampicillin (SigmaAldrich, Gillingham, Dorset, UK) and were screened for bla FRI-1 by PCR before WGS.
WGS was performed on both the clinical isolate and FRI-2 transformant using a Hiseq sequencer (Illumina) and the resulting data were analysed using an in-house bioinformatics pipeline; resistance genes were identified by mapping reads against a library curated in-house from publically accessible databases. 10 Transformant reads were assembled into contigs using SPAdes 3.5.0 (http://bioinf.spbau.ru/spades), with K-mer values of 21, 33, 55 and 77. Plasmid contigs were extracted from the known E. coli host genome and gaps were closed by PCR and subsequent Sanger sequencing. Plasmid replicon types were determined using PlasmidFinder 11 on the Center for Genomic Epidemiology platform (https://cge.cbs.dtu.dk/services/ ). Genes were inferred and annotated using PROKKA 12 and BLAST. ST was determined in silico (https://pubmlst.org/ecloacae/). 13 Typing was carried out by PFGE of XbaI-digested genomic DNA.
Nucleotide sequence accession numbers
The nucleotide sequence data have been submitted to the GenBank nucleotide database under accession no. KX620467 for bla FRI-2 and KX912253 for the plasmid pJF-587.
Results and discussion
Resistance to carbapenems in Enterobacter spp. isolates is encountered frequently in the UK, but is mainly associated with a combination of several mechanisms including production of ESBL, increased efflux, porin alteration and/or overproduction of the intrinsic AmpC enzyme, 14, 15 hence the difficulty in relating (Table 1) .
A bla FRI-1-like gene was detected by in-house multiplex PCR, and was confirmed by Sanger sequencing of the amplicon. Subsequent analysis of WGS data of the E. cloacae complex isolate identified an ORF of 885 bp , which showed 97% nucleotide identity with bla FRI-1 . The newly named bla FRI-2 was predicted to encode a 294 amino acid protein, which shares 275/294 (94%) amino acid identity with FRI-1 (Figure 1a) . The other antibiotic resistance genes detected by WGS were bla ACT-2 , encoding a chromosomal AmpC enzyme, fosA, and a mutation in gyrA at position 83 (S!T). WGS of the transformant indicated bla FRI-2 was located on a 108 kb IncF/IncR plasmid, which did not share significant homology with any plasmid sequences in public databases. The LysR family regulator (FRI-R) was present downstream of bla FRI-2 and shared 95.8% identity with FRI-R described downstream of bla FRI-1 ; the ISEc8 element described upstream of bla FRI-1 was absent. 5 Downstream of bla FRI-2 , a MerR family transcriptional regulator was identified where ISEc14 was previously characterized near bla FRI-1 (Figure 1b) . One hundred and nineteen ORFs were identified on the 108 kb plasmid with 69 ORFs showing no similarity with published sequences. The remaining ORFs encoded for genes involved in plasmid conjugation and partitioning; no other resistance genes or any virulence genes were encoded on the plasmid.
The G ! C content for both bla FRI-2 and bla FRI-1 was similar (39%); however, the plasmid pJF-587 bearing bla FRI-2 had a G ! C content of 52% suggesting horizontal acquisition of the gene.
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France and who had travelled to Switzerland. 5 The UK patient had no travel history, and the only risk factor potentially associated with acquiring the FRI-2-positive E. cloacae complex strain was previous hospitalization in two hospitals in North West England. PFGE typing of the E. cloacae failed due to DNA degradation so no comparison with E. cloacae isolates from either of the hospitals attended by the patient could be performed. The WGS data analysis showed that the FRI-2-positive E. cloacae isolate belonged to a novel ST (ST829).
To the best of our knowledge, this is only the second report globally of a FRI family carbapenemase. FRI-2 has substantial sequence divergence from FRI-1 (6% amino acid differences), and may therefore represent a distinct gene 'escape' event from an unidentified source species. Other class A carbapenemases previously identified in the Enterobacter genus include KPC and rarer carbapenemases, such as IMI and GES. The identification of bla IMI in E. coli and Klebsiella variicola demonstrates that despite the rare isolation of such carbapenemases, they have the potential to transfer within and between species. 16, 17 The presence of ISs and the location of FRI-2 on a plasmid highlight this potential. The identification of FRI-2 in a clinical setting in the UK demonstrates the role of phenotypic tests to detect carbapenemase activity. When molecular assays are negative for the 'big 5' carbapenemase families, microbiologists should consider the possibility of other carbapenemase types that are currently rare, but have the potential to become more significant public health problems. Meunier et al. Identification of FRI-2 carbapenemase in the UK JAC
